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Abstract The insulin-like growth factor type 1 receptor
(IGF1R) is involved in progression of breast cancer and
resistance to systemic treatment. Targeting IGF1R signal-
ing may, therefore, be beneficial in systemic treatment. We
report the effect of IGF1R expression on prognosis in
invasive ductal breast carcinoma (IDC), the most common
type of breast cancer. Immunohistochemistry was per-
formed on tumor tissue of a consecutive cohort of 429
female patients treated for operable primary IDC. Associ-
ations between IGF1R expression with clinicopathological
parameters, disease free survival (DFS) and breast cancer
specific survival (BCSS) were evaluated by multivariate
analyses focusing on ER-positive and triple negative IDC
(TN-IDC). To enlarge the TN-IDCs cohort, we analyzed a
combined dataset of 51 TN-IDC tumors from our series with
64 TN-IDCs with similar clinicopathological parameters.
Patients with tumors expressing cytoplasmic IGF1R have a
longer DFS and BCSS (DFS: HR 0.46, 95% CI 0.27–0.49,
P = 0.005, BCSS: HR 0.38, 95% CI 0.19–0.74, P = 0.005).
This effect was most prominent in ER-positive tumors.
However, in a combined series of 105 TN-IDCs cytoplasmic
IGF1R expression was associated with a shorter DFS
(HR = 2.29, 95% CI 1.08–4.84, P = 0.03), also when
combined in a multivariate model, including well-known
prognostic factors (HR 2.06; 95% CI 0.95–4.47; P = 0.07).
IGF1R expression in ER-positive IDC is strongly related to a
favorable DFS and BCSS, but to a shorter DFS in TN-IDC
tumors. This divergent effect of IGF1R expression in sub-
groups of IDC may affect selection of patients for IGF1R
targeted therapy.
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Introduction
Signaling via the insulin-like growth factor type 1 receptor
(IGF1R) plays a crucial role in proliferation, cell survival,
invasion, and metastatic behavior of many cancers,
including breast cancer [1, 2]. In addition, IGF1R is
implicated in resistance to chemotherapy, hormonal ther-
apy, Human Epidermal Growth Factor Receptor 2 (HER2)
and Epidermal Growth Factor Receptor (EGFR) directed
therapies [3–5].
IGF1R is a transmembrane tyrosine kinase receptor
activated by binding of IGF-1 or -2 [6]. Subsequently,
signaling occurs via Src homology 2 domain-containing
protein, insulin receptor substrates, phosphatidylinositol-3-
kinase/Akt, and mitogen-activated protein kinase pathways
[7–9]. High IGF1R expression levels have been reported in
a wide range of human malignancies, but correlations with
tumor characteristics and outcome are infrequently found
[10]. Based on in vitro and in vivo data with IGF1R anti-
bodies and tyrosine kinase inhibitors, responses are
expected in a variety of carcinomas [3, 11–14]. IGF1R
targeted therapy in breast cancer is particularly interesting,
because synergy with anti-hormonal therapy and targeting
of related receptor tyrosine kinases HER2 and EGFR has
been shown [15–17]. There is evidence coming from cell
line studies suggesting IGF1R-signaling has different
effects on cellular characteristics like proliferation and
migration in ER-negative tumors as opposed to ER-posi-
tive tumors [18–20]. However, it is still unclear which
factors contribute to sensitivity to anti-IGF1R directed
therapy as no biomarker is available yet to select patients
and tumor types.
Breast cancer is a heterogeneous disease with different
sensitivity to drug treatment and outcome between differ-
ent histological and molecular subtypes [21, 22]. Previous
studies showed high IGF1R expression in human breast
carcinomas,[23–27] and several studies showed correla-
tions of IGF1R expression with estrogen receptor expres-
sion and well-differentiated carcinomas [23, 27, 28]. A
special subgroup of breast carcinomas, called triple nega-
tives (TNs), defined by absence of estrogen receptor (ER),
progesterone receptor (PR), and HER2 expression, has a
worse prognosis and lacks a scaffold for conventional
targeted treatments [29]. Identification of new targets in
TNs are warranted to extend the armamentarium for this
relatively poor prognostic subgroup of breast cancer. The
IGF1R could be a target and thereby providing new treat-
ment options.
In the current study, IGF1R expression was investigated
in a consecutive cohort of patients with invasive ductal
carcinomas (IDCs) of the breast. In this way, the value of
IGF1R expression in the most prevalent histological sub-
type can be related to patient and tumor characteristics,
molecular markers, and prognosis. For above-mentioned
reasons special attention will be put on TN-IDCs. For the
latter, we combined two datasets of TN-IDCs with similar
clinicopathological parameters.
Patients, materials, and methods
Patients
A consecutive cohort of 429 female patients treated for a
primary local or locally advanced invasive ductal breast
carcinoma, as defined by the WHO classification [30] at the
University Medical Center Groningen between January
1996 and December 2005 was included in this study. In this
same period 26 patients presented with a synchronous
(n = 4) or metachronous (n = 18) contralateral breast
tumor or a recidive tumor (n = 4), these patients were not
included in our cohort.
All patients received local treatment, i.e., breast con-
serving therapy including radiotherapy or ablative surgery,
both with lymph node staging (sentinel node procedure
and/or axillary dissection). Local therapy was followed by
chemotherapy in 118 patients (96/118 anthracycline-con-
taining chemotherapy (AC/FEC/CAF); 20/118 cyclophos-
phamide, methotrexate, and fluorouracil (CMF); 2/118
taxane based). In 55 patients chemotherapy was combined
with endocrine treatment, 97 other patients received only
endocrine systemic treatment (total n = 152; 121/146
tamoxifen; 24/146 aromatase inhibitor; in 7 patients who
remained premenopausal after received chemotherapy, a
LHRH analogue was added). Only 4 patients received
herceptin. Patient and tumor characteristics and data on
follow-up were obtained from hospital records (Table 1).
The medical ethical committee of the University Medical
Center Groningen approved this study.
To study a subgroup of patients in more detail, 51 triple
negative breast carcinomas (TN-IDCs) from the cohort
described above (Groningen dataset) were combined with a
previously described cohort of 71 TN tumors (Amsterdam
dataset) [31], from which 64 were invasive ductal carci-
nomas and evaluable for IGF1R expression in our study.
The two populations were similar with regard to patient
and tumor characteristics, local and systemic therapy and
survival (Supplementary Table 1).
Characterization of breast carcinomas
by immunohistochemistry
A tissue microarray was constructed as previously descri-
bed [32, 33]. TMA sections were stained with antibodies
against IGF1R, insulin receptor (IR), phosphorylated-Akt
(p-Akt), ER, PR, and HER2. Specific details of the
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antibodies and their antigen retrieval methods used are
summarized in Supplementary Table 2. The immunohis-
tochemical methods in general were previously described
by van der Vegt et al. [34] for ER, PR, and HER2 staining.
Scoring of the immunohistochemical staining was
performed by a consultant breast pathologist (JW). ER and
PR were assessed based on the percentage of tumor cells
showing positive nuclear staining and were considered
positive if nuclear staining was present in C10% of the
cells, according to Dutch guidelines (www.oncoline.nl).
HER2 expression was scored as follows: 0 for no staining
at all or membrane staining in\10% of the tumor cells; 1?
for a faint/barely perceptible partial membrane staining in
[10% of the tumor cells; 2? for weak to moderate com-
plete membrane staining in [10% of the tumor cells; 3?
for strong complete membrane staining in [10%. HER2
was considered positive if the score was 3?. IR and p-Akt
were considered positive if either membranous or cyto-
plasmic staining was present in C10% of the cells.
IGF1R expression, analogue to HER2 expression, was
considered positive with strong complete staining pattern in
[10% of tumor cells as depicted in Fig. 1. To confirm the
robustness of the staining pattern for IGF1R using the
24–31 antibody, a tissue microarray of 50 consecutive
invasive breast carcinomas was stained using the same
clone provided by another supplier (clone 24–31, Neo-
markers, Fremont CA, USA; dilution 1/800). Each indi-
vidual core of both stained tissue microarrays can be seen
at http://telepathology.nki.nl (Login: igf1r, Password: nki-
avl). For all stainings, the highest score out of three cores
from the same tumor was used for the analysis. If one or
two cores out of three failed, the highest value of the
remaining core(s) was included in the analysis. Only the
invasive tumor component was considered when judging
the staining. When no (invasive) tumor cells were available
in the sample, the result was considered ‘missing’ in the
statistical analysis.
Statistical analysis
Since the clinical relevance of IGF1R localization is yet
unknown, separate analyses were conducted for 1. positive
cytoplasmic IGF1R staining vs. no cytoplasmic staining, 2.
positive membranous vs. no membranous staining and 3.
any positive staining (cytoplasmic, membranous, or both)
vs. negative staining pattern (further addressed as ‘‘overall
IGF1R expression’’).
Univariate and multiple logistic regression analyses
were performed to evaluate the associations of IGF1R
expression with clinical (age, menopausal status, lymph
node status, surgical, and adjuvant therapy), tumor (size
and differentiation grade), and immunohistochemical (ER,
PR, IR, HER2, and p-Akt) characteristics. Multivariate Cox
regression analysis was used to explore the relationship
between IGF1R and the following survival endpoints; (1)
disease free survival (DFS), defined as time to any
Table 1 Patient and tumor characteristics
N = 429 %
Age at diagnosis (years)
Median, range 59 (27–91)




0–2 cm 228 54.4
[2–5 cm 161 38.3
















Adjuvant systemic treatment 215 50
Chemotherapy only 63 15
Hormonal therapy only 97 23
Chemotherapy combined with hormonal therapy 55 13









Median, range 55 (0–134)
Locoregional recurrence 18 4
Distant metastasis 55 12
Breast cancer related death 36 8
IDC invasive ductal carcinoma no special type, DCIS ductal carci-
noma in situ, BCT breast conserving therapy
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recurrence (local or regional or distant), and (2) breast
cancer specific survival (BCSS). Clinicopathological vari-
ables that had a significant univariate association (Tables 2,
3) were entered simultaneously in a multivariate Cox
regression model. Log-rank tests were performed to eval-
uate the difference in group-specific survival which is
illustrated by Kaplan–Meier plots.
All statistical analyses were performed using the sta-
tistical package SPSS 16.0 (SPSS inc., Chicago, IL, USA).
Findings
Immunohistochemistry
Immunohistochemistry for IGF1R could be evaluated in
368 cases (86%). In case IGF1R was present, the intensity
of the staining was strong and uniformly present in all
tumor cells in 295 cases (80%). Pure membranous IGF1R
expression was present in 8%, pure cytoplasmic in 21%,
Fig. 1 a–f Location patterns of
IGF-1R immunohistochemical
staining: a, b cytoplasmic
(magnification 910, 920);
c, d membranous (910, 920),
and e, f membranous and
cytoplasmic (910, 920)
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and both membranous and cytoplasmic staining in 51%. An
overview of other assessed immunohistochemical markers
is summarized in Supplementary Table 3.
Association of IGF1R staining pattern
with clinicopathological parameters
The univariate association of IGF1R cytoplasmic and
membranous expression with patient and tumor character-
istics is summarized in Supplementary Table 4. In a multiple
logistic regression model, including tumor size, differentia-
tion grade of the tumor, ER and PR expression, ER was
strongly associated with IGF1R cytoplasmic expression
(OR = 4.18; 95% CI 2.07–8.44, P \ 0.001) and IGF1R
overall staining (OR = 3.22; 95% CI 1.54–6.74, P = 0.002).
No relation with p-Akt or IR expression was found.
Prognostic relevance of IGF1R staining pattern
Cytoplasmic, but not membranous or overall IGF1R
expression was strongly associated with prolonged DFS
(HR 0.46, 95% CI 0.27–0.49, P = 0.005) and increased
BCSS (HR 0.38, 95% CI 0.19–0.74, P = 0.005) (Figure 2).
Tumor size, differentiation grade, and PR were multi-
variately significant factors for DFS (Table 4). Interest-
ingly, while in ER-positive tumors cytoplasmic IGF1R
expression is a favorable prognostic factor, in ER-negative
tumors this effect is lost and membranous staining is related
to a worse prognosis (DFS) (log-rank P = 0.02) (Fig. 3).
Subsequently, significant univariate parameters for BCSS
(Table 3) were analyzed by multivariate Cox regression in
which differentiation grade and HER2 were prognostic
factors (Supplementary Table 5).
Effect of IGF1R expression in triple negative breast
carcinomas
This interesting result, i.e., a possible opposite effect of
IGF1R expression on prognosis of ER-positive versus
Table 2 Univariate Cox regression analysis of clinicopathological
variables and disease free survival (DFS)
HR 95% CI P value





0–2 cm 1 \0.001
[2–5 cm 2.07 1.15–3.75 0.02
[5 cm 5.62 2.59–12.19 \0.001
Differentiation grade
Well 1 \0.001
Moderate 2.49 0.93–6.64 0.07
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ER-negative tumors, led us to investigate the effect of
IGF1R expression in a cohort of TN-IDCs. Because there
were only 51 such cases in our cohort (University Medical
Center Groningen; referred to as Groningen dataset), we
combined these with a previously described cohort of 64
evaluable cases of TN-IDCs from another center (Nether-
lands Cancer Institute/Antoni van Leeuwenhoek Hospital;
referred to as Amsterdam dataset) [31] with similar patient
and tumor characteristics and survival (Supplementary
Table 1). For the Amsterdam cohort, the majority of patients
was treated by breast conserving therapy (BCT) including
post-operative radiotherapy, whereas for the Groningen
dataset approximately halve of the patients were treated by
BCT. Immunohistochemistry for IGF1R could be evaluated
in 105 triple negative cases (91%). IGF1R was expressed in
52 cases (45%). Pure cytoplasmic IGF1R expression was
present in 11 cases (10%) and pure membranous IGF1R
expression in 11 cases (10%). In total, 30 cases (26%) had
combined membranous and cytoplasmic staining. We found
no association between membranous or cytoplasmic IGF1R
expression and clinicopathological parameters.
In the combined patient cohort of 105 TN-IDCs, cyto-
plasmic IGF1R expression has an unfavorable prognostic
impact on DFS (cytoplasmic: HR = 2.29, 95% CI 1.08–
4.84, P = 0.03; membranous: HR 1.98; 95% CI 0.94–4.17,
P = 0.07). Comparable direction and magnitude of effects
were seen in both triple negative databases separately
(cytoplasmic HR 2.99 and 1.83 resp.; membranous HR
1.58 and 1.83 resp.), although not consistently statistically
significant, most likely due to lower numbers in the sepa-
rate databases, and thus reduced power. In a multivariate
analysis, including all well-known prognostic clinicopath-
ological parameters, cytoplasmic IGF1R expression was a
near-significant prognostic factor for DFS (HR 2.06; 95%
CI 0.95–4.47; P = 0.07) (Table 5).These same associa-
tions were also found when only time to distant metastasis
A B
Fig. 2 Kaplan–Meier plots of associations of IGF1R expression with disease free survival (a) and breast cancer specific survival (b) in months
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was tested (cytoplasmic: HR 2.69, 95% CI 1.16–6.22,
P = 0.02; membranous: HR 2.74, 95% CI 1.18–6.32, P =
0.02). Both cytoplasmic (HR 2.43, 95% CI 1.02–5.8, P =
0.04) and membranous staining (HR 2.64, 95% CI
1.11–6.31, P = 0.03) were multivariately related to time
to distant metastases. No association between IGF1R
expression and BCSS could be demonstrated in triple
negative cases.
Discussion
In this study, we found that cytoplasmic expression of
IGF1R in ER-positive invasive ductal breast carcinomas is
associated to a more favorable prognosis, while in triple
negative breast carcinomas IGF1R expression is associated
to a poor outcome. This study underlines that the clinical
impact of transmembrane tyrosine kinase receptor expres-
sion should be interpreted in the context of the carcinoma
subtype, such as co-expression with hormone receptors. We
found IGF1R expression in 80% in our series of invasive
ductal breast carcinomas (IDC). The majority of these
tumors (62%) had combined cytoplasmic and membranous
staining. Since the clinical relevance of IGF1R localization
is yet unknown and our goal of the present study was eval-
uation of a candidate prognostic biomarker that would be
clinical applicable, separate analyses were conducted for
cytoplasmic, membranous, and overall staining. Cytoplas-
mic IGF1R staining highly correlated with hormone recep-
tor expression, well differentiated breast carcinomas, and to
a more favorable prognosis. This prognostic effect occurred
specifically in ER-positive breast carcinomas. Since cyto-
plasmic staining patterns of tumor samples incorporated on
the same TMA-slide show differential staining intensity and
subsequent significant correlation with biologic plausible
factors, we considered this not an artifact but a relevant
observation which should not a priori be ignored. Moreover,
the robustness of IGF1R staining intensity and staining
pattern was confirmed using an antibody of the same clone
provided by another supplier on a tissue microarray of 50
randomly chosen invasive breast carcinomas.
Although the biologic significance of cytoplasmic
localization of the IGF1R has received little attention in the
literature up till now, cytoplasmic localization has been
observed before. Confocal microscopy images studying
subcellular localization of IGF1R show cytoplasmic stain-
ing [35, 36]. Some have reported cytoplasmic IGF1R
staining by IHC [37, 38], while others have chosen to ignore
cytoplasmic staining, although endoplasmatic staining had
been present [39]. Biologically cytoplasmic IGF1R has
been linked to mutant receptors which show abolished cell
surface expression and endoplasmatic retention of the
receptor due to failure to traffic to the cell membrane [40].
Also, accumulation of IGF1R into the cytoplasm has been
observed after internalization and intracellular trafficking
induced by binding of ligand or antibodies, resulting in
receptor degradation [36]. Most of the biologic effects of
the IGF1R have been ascribed to its tyrosine kinase activity,
which propagates signaling through the phosphatidylinosi-
tol 3-kinase and mitogen-activated protein kinase pathways.
Recently, however, IGF1R translocation to the nucleus has
been described and shown to activate transcription but not
alter its kinase-dependent signaling [41, 42]. This is ana-
logue to the earlier observation that ErbB family proteins
are expressed in the nucleus and can function as transcrip-
tional regulators [43]. Although cytoplasmic or nuclear
HER2 staining by IHC in clinical tumor samples is not
considered to be relevant for prognosis or selection of
HER2 targeted therapy, the biological relevance of nucleo-
cytoplasmic trafficking has been accepted.
In our samples, nuclear IGF1R expression did not
become evident. Of particular interest is the relation of
IGF1R localization with ER expression. Interaction of
Table 3 Multivariate Cox Regression on disease free survival
(number of events = 61; number of patients = 341)
HR 95% CI P value
Tumor size
0–2 cm 1 0.05
[2–5 cm 1.29 0.71–2.35 0.41
[5 cm 2.92 1.21–7.05 0.02
Differentiation grade
Well 1 0.02
Moderate 2.45 0.92–6.57 0.08
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IGF1R and ER has been shown in numerous studies, but
this interaction also involves physical co-localization.
Reported co-localization of the ER, which is generally
localized in the nucleus, with IGF1R at the cell membrane
underscores the diversity of receptor localization [35].
Taken together, these data suggest that protein locali-
zation of tyrosine kinase receptors is a highly dynamic
biological process. The specific details of functional
implications of IGF1R cytoplasmic localization need to be
appreciated in future studies.
In previous studies, similar associations of ER and
IGF1R expression were reported [27, 28, 44], e.g., Ueda
et al. [27] described a favorable prognosis for IGF1R
expression in ER-positive carcinomas. In triple negative
breast carcinomas (TN-IDCs) we found IGF1R expression
in 65% of the cases. In these tumors cytoplasmic staining
showed some relation to shorter DFS, although no effect
was found on overall survival rates. In line with our results,
Railo et al. [45] reported similar worse survival rates in
ER-negative IGF1R expressing breast carcinomas.
Our observation of a different association between
IGF1R expression and prognosis in ER-positive versus
ER-negative carcinomas is supported by in vitro studies. In
breast cancer cell lines IGF1R and ER synergistically
stimulate proliferation [20], but in the absence of ER,
IGF1R activation fails to induce mitogenesis, while its
migratory actions are retained [18, 19].
High circulating IGF1 levels are by now a well-estab-
lished risk factor in women for developing breast cancer
[46, 47], and a most recent collaborative analysis of 17
prospective studies established that the risk-association is
confined to ER-positive tumors [48]. These data strongly
support a notion of altered biologic and prognostic signif-
icance of IGF1 and IGF1R in ER-positive vs. ER-negative
tumors as presented in our study.
Most likely, IGF1R expressing, ER-positive carcinomas
represent a large subclass of breast carcinomas with pre-
sumably a distinct biology and an excellent prognosis. It
could be hypothesized that well-differentiated, ER-positive
breast cancers retain physiological growth control by ER
A B
Fig. 3 Kaplan–Meier plots of group-specific associations of IGF1R expression with disease free survival in ER-positive (a) and ER-negative
(b) breast carcinomas
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and IGF1R signaling, while in ER-negative carcinomas
IGF1R expression confers primarily metastatic capacities.
Hormone receptor positive invasive ductal breast can-
cers are nowadays treated with adjuvant tamoxifen and/or
aromatase inhibitors during 5 years or longer. Long-term
survival benefit of hormonal therapy is reported to be
4–12% [21]. Because IGF1R and hormone receptors clo-
sely interact, a combination of hormonal therapy with
IGF1R drugs may help to block all mitogenic hormonal
responses. Also, as modulations of the IGF1R system have
been implicated in development of resistance to endocrine
therapies, IGF1R directed therapy may overcome or pre-
vent development of hormone therapy resistance [4, 49,
50]. Indeed, synergistic effects of IGF1R targeting drugs
with hormonal therapies have been reported in vivo [3].
Therefore, we suppose that IGF1R directed therapy may
complement therapy for hormone receptor positive breast
cancers, in particular in case of constitutive or acquired
resistance to endocrine therapy.
Our patient cohort covers a considerable time span, in
which the indications and therapeutic options for surgical
Table 5 Multivariate Cox regression on disease free survival in triple
negative invasive ductal breast carcinomas (number of events = 28,
number of patients = 101)
HR 95% CI P value
Tumor size
\2 cm 1 0.15










Table 4 Univariate Cox regression analysis of patient, tumor and
treatment characteristics with Breast Cancer Specific Survival (BCSS)
HR 95% CI P value





0–2 cm 1 \0.001
[2–5 cm 2.59 1.17–5.73 0.02
[5 cm 7.41 2.84–19.33 \0.001
Differentiation grade
Well 1 \0.001
Moderate 6.78 0.87–52.51 0.07
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and systemic treatment have further been developed and
adjusted. Surgical treatment (mastectomy vs. lumpectomy
followed by radiation), received chemotherapy, and hor-
monal therapy were included in our multivariate survival
models and group by group analysis was conducted for
anthracycline-containing chemotherapy versus no chemo-
therapy and for tamoxifen versus no hormonal treatment
(data not shown). Herein we found no evidence that the
survival benefit of IGF1R expression on prognosis in our
study was compounded by interaction with adjuvant sys-
temic therapy. However, changing chemotherapy regi-
mens, different hormonal treatment and shifting indications
for adjuvant treatment over this period of time could not
entirely be accounted for in our models.
In the Amsterdam dataset of TN-IDC more patients
were treated with breast conserving surgery followed by
radiation than in our cohort. Breast conserving surgical
therapy bears a slightly increased risk on local recurrence
of the tumor. However, our finding of an unfavorable
prognostic impact of IGF1R on DFS in this population held
true when time to distant metastasis was tested and was not
attributed to local recurrences.
The present database was considered less appropriate for
studying effects on prognosis in HER2 positive tumors,
because herceptin had not yet been introduced as a standard
adjuvant systemic treatment in this patient group during the
inclusion period of this study. Also, correlations with
HER2 may be inaccurate, since only 3? HER2 cases were
considered positive, and 2? cases were not subjected to
FISH analysis.
Activation of PI3K signaling, which among multiple
other signals is induced by IGF1R, occurs often in breast
carcinomas [51] and has been related to limited sensitivity to
HER2 directed therapy [52]. We, however, found no cor-
relation of IGF1R expression with staining of phosphory-
lated-Akt or PTEN, neither with RNA expression of PI3K
pathway related genes (data not shown). Therefore, we
could not show PI3K to be a dominant pathway emerging
from high IGF1R expression and we can only speculate on
the functional significance of positive IGF1R expression.
Since an IGF-1 signature has been published predicting
worse prognosis of ER-positive breast carcinomas [53] it is
of interest to test whether the presence of such a signature is
related to IGF1R expression on the protein level.
As the IGF1R is highly homologous to the IR, and they
share several functions [1], IR expression was studied but
no relation with clinicopathological parameters or IGF1R
expression pattern could be shown. Although there are data
suggesting IR is also a favorable prognostic factor [54, 55]
we could not reproduce these results. Among other expla-
nations, using antibodies with different specificity for
(splice variants) of IR and IGF1R-IR hybrids may have
played a role.
Interestingly, Law et al. [56] reported that phosphory-
lated IGF1R and insulin receptor (IR) can be found in all
breast carcinoma subtypes and is related to a poor survival.
Whether detection of phosphorylated IGF1R and IR out-
performs the detection of IGF1R expression as presented
here as a biomarker is subject of ongoing studies.
In TN-IDCs, inhibition of the IGF1R-mediated signaling
is likely to have a clear beneficial effect as has been shown
for a mouse model carrying basal type breast carcinomas
[57]. Within this perspective, clinical phase trials of IGF1R
antibodies and tyrosine kinase inhibitors or antibodies
blocking the IGF1R signaling should focus both on ER-
positive as well as TN-IDCs. With regard to the importance
of cytoplasmic IGF1R expression, treatment with tyrosine
kinase inhibitors may be advantageous over antibodies.
The clinical development of antibodies against the IGF1R
membrane receptor, however, is far ahead of the tyrosine
kinase inhibitors, which is also understandable with regard
to the expected side effects of such a treatment.
In conclusion, IGF1R expression in invasive ductal
breast carcinomas is a strong favorable prognostic factor in
ER-positive, but highly likely an unfavorable factor in TN-
IDCs. The findings of our study combined with those of
others strongly suggest that targeting IGF1R signaling is
likely to be a promising treatment strategy of IGF1R
expressing breast carcinomas. Clearly, further validation
studies according to well established criteria are required to
implement the IGF1R as a biomarker that could assist
making a rational choice for IGF1R targeted therapy [58].
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